Which has better valuation and earnings, LSTA or PLYX?

Polaryx Therapeutics has lower revenue, but higher earnings than Lisata Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lisata Therapeutics $170K 191.85 -$16.59M -$1.86 N/A Polaryx Therapeutics N/A N/A N/A N/A N/A

Is LSTA or PLYX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Lisata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lisata Therapeutics N/A -103.54% -83.08% Polaryx Therapeutics N/A N/A N/A

Do analysts recommend LSTA or AADI?

Lisata Therapeutics currently has a consensus price target of $15.00, indicating a potential upside of 318.99%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Lisata Therapeutics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is LSTA or RANI more profitable?

Lisata Therapeutics' return on equity of -103.54% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lisata Therapeutics N/A -103.54% -83.08% Rani Therapeutics N/A -206.46% -83.95%

Is ENGN or LSTA more profitable?

enGene's return on equity of -55.83% beat Lisata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -55.83% -45.74% Lisata Therapeutics N/A -103.54% -83.08%

Do analysts prefer LSTA or CYPH?

Lisata Therapeutics presently has a consensus price target of $15.00, indicating a potential upside of 318.99%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Cypherpunk Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LSTA or CYPH more profitable?

Cypherpunk Technologies' return on equity of -48.33% beat Lisata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lisata Therapeutics N/A -103.54% -83.08% Cypherpunk Technologies N/A -48.33% -42.21%

Lisata Therapeutics (LSTA) Competitors

$3.58 +0.33 (+10.15%)

Closing price 04:00 PM Eastern

Extended Trading

$3.54 -0.04 (-1.26%)

As of 07:23 PM Eastern

Compare

LSTA vs. PLYX, AADI, RANI, ENGN, and CYPH

Should you buy Lisata Therapeutics stock or one of its competitors? MarketBeat compares Lisata Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lisata Therapeutics include Polaryx Therapeutics (PLYX), Aadi Bioscience (AADI), Rani Therapeutics (RANI), enGene (ENGN), and Cypherpunk Technologies (CYPH). These companies are all part of the "pharmaceutical products" industry.

How does Lisata Therapeutics compare to Polaryx Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Polaryx Therapeutics has lower revenue, but higher earnings than Lisata Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	191.85	-$16.59M	-$1.86	N/A
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A

In the previous week, Polaryx Therapeutics had 4 more articles in the media than Lisata Therapeutics. MarketBeat recorded 5 mentions for Polaryx Therapeutics and 1 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 1.87 beat Polaryx Therapeutics' score of 1.16 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lisata Therapeutics	Very Positive
Polaryx Therapeutics	Positive

Lisata Therapeutics presently has a consensus target price of $15.00, indicating a potential upside of 318.99%. Polaryx Therapeutics has a consensus target price of $10.00, indicating a potential upside of 257.14%. Given Lisata Therapeutics' higher possible upside, equities analysts plainly believe Lisata Therapeutics is more favorable than Polaryx Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

8.9% of Lisata Therapeutics shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Polaryx Therapeutics' return on equity of 0.00% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
Polaryx Therapeutics	N/A	N/A	N/A

Summary

Lisata Therapeutics and Polaryx Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Lisata Therapeutics compare to Aadi Bioscience?

Lisata Therapeutics (NASDAQ:LSTA) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Lisata Therapeutics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Lisata Therapeutics currently has a consensus price target of $15.00, indicating a potential upside of 318.99%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Lisata Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Lisata Therapeutics has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

In the previous week, Lisata Therapeutics and Lisata Therapeutics both had 1 articles in the media. Lisata Therapeutics' average media sentiment score of 1.87 beat Aadi Bioscience's score of 0.91 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lisata Therapeutics	Very Positive
Aadi Bioscience	Positive

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Lisata Therapeutics has higher earnings, but lower revenue than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	191.85	-$16.59M	-$1.86	N/A
Aadi Bioscience	$25.07M	4.65	-$65.76M	-$2.35	N/A

Summary

Lisata Therapeutics beats Aadi Bioscience on 9 of the 14 factors compared between the two stocks.

How does Lisata Therapeutics compare to Rani Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Lisata Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

Lisata Therapeutics has higher earnings, but lower revenue than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	191.85	-$16.59M	-$1.86	N/A
Rani Therapeutics	$1.63M	68.07	-$29.67M	-$0.41	N/A

Lisata Therapeutics' return on equity of -103.54% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
Rani Therapeutics	N/A	-206.46%	-83.95%

Lisata Therapeutics presently has a consensus target price of $15.00, indicating a potential upside of 318.99%. Rani Therapeutics has a consensus target price of $8.75, indicating a potential upside of 876.89%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Rani Therapeutics is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Rani Therapeutics had 3 more articles in the media than Lisata Therapeutics. MarketBeat recorded 4 mentions for Rani Therapeutics and 1 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 1.87 beat Rani Therapeutics' score of 0.82 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lisata Therapeutics	Very Positive
Rani Therapeutics	Positive

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Rani Therapeutics beats Lisata Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Lisata Therapeutics compare to enGene?

enGene (NASDAQ:ENGN) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

enGene's return on equity of -55.83% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-55.83%	-45.74%
Lisata Therapeutics	N/A	-103.54%	-83.08%

In the previous week, enGene had 9 more articles in the media than Lisata Therapeutics. MarketBeat recorded 10 mentions for enGene and 1 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 1.87 beat enGene's score of 0.20 indicating that Lisata Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
enGene	Neutral
Lisata Therapeutics	Very Positive

enGene has a beta of -0.29, indicating that its stock price is 129% less volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market.

enGene currently has a consensus target price of $12.68, suggesting a potential upside of 612.46%. Lisata Therapeutics has a consensus target price of $15.00, suggesting a potential upside of 318.99%. Given enGene's stronger consensus rating and higher possible upside, equities analysts plainly believe enGene is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

64.2% of enGene shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 10.5% of enGene shares are held by company insiders. Comparatively, 9.1% of Lisata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Lisata Therapeutics has higher revenue and earnings than enGene. Lisata Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.25	N/A
Lisata Therapeutics	$170K	191.85	-$16.59M	-$1.86	N/A

Summary

enGene beats Lisata Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Lisata Therapeutics compare to Cypherpunk Technologies?

Lisata Therapeutics (NASDAQ:LSTA) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Lisata Therapeutics has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market.

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Lisata Therapeutics presently has a consensus price target of $15.00, indicating a potential upside of 318.99%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cypherpunk Technologies' return on equity of -48.33% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
Cypherpunk Technologies	N/A	-48.33%	-42.21%

In the previous week, Lisata Therapeutics and Lisata Therapeutics both had 1 articles in the media. Lisata Therapeutics' average media sentiment score of 1.87 equaled Cypherpunk Technologies'average media sentiment score.

Company	Overall Sentiment
Lisata Therapeutics	Very Positive
Cypherpunk Technologies	Very Positive

Cypherpunk Technologies has lower revenue, but higher earnings than Lisata Therapeutics. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	191.85	-$16.59M	-$1.86	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A

Summary

Lisata Therapeutics beats Cypherpunk Technologies on 6 of the 11 factors compared between the two stocks.

Get Lisata Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LSTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LSTA vs. The Competition

Export

Metric	Lisata Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$32.61M	$3.32B	$6.31B	$12.59B
Dividend Yield	N/A	2.28%	2.68%	5.22%
P/E Ratio	-1.92	18.07	21.13	26.63
Price / Sales	191.85	326.58	546.66	114.76
Price / Cash	N/A	54.19	27.44	37.60
Price / Book	2.16	6.84	9.95	6.88
Net Income	-$16.59M	$24.15M	$3.56B	$336.73M
7 Day Performance	14.01%	1.93%	2.12%	4.19%
1 Month Performance	N/A	N/A	N/A	-0.08%
1 Year Performance	39.84%	62.98%	36.32%	40.26%

Lisata Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LSTA Lisata Therapeutics	2.2578 of 5 stars	$3.58 +10.2%	$15.00 +319.0%	+27.0%	$32.61M	$170K	N/A	30	News Coverage Positive News Gap Up High Trading Volume
PLYX Polaryx Therapeutics	4.648 of 5 stars	$2.51 -2.7%	$10.00 +298.4%	N/A	$118.05M	N/A	N/A	11	Positive News
AADI Aadi Bioscience	N/A	$4.77 +6.2%	N/A	+179.3%	$117.81M	$25.07M	N/A	40	High Trading Volume
RANI Rani Therapeutics	3.3903 of 5 stars	$0.95 +1.0%	$8.75 +821.1%	+70.5%	$117.69M	$1.63M	N/A	110
ENGN enGene	4.1029 of 5 stars	$1.72 -2.3%	$12.68 +637.3%	-52.2%	$115.21M	N/A	N/A	31

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LSTA) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lisata Therapeutics (LSTA) Competitors

LSTA vs. PLYX, AADI, RANI, ENGN, and CYPH

How does Lisata Therapeutics compare to Polaryx Therapeutics?

Summary

How does Lisata Therapeutics compare to Aadi Bioscience?

Summary

How does Lisata Therapeutics compare to Rani Therapeutics?

Summary

How does Lisata Therapeutics compare to enGene?

Summary

How does Lisata Therapeutics compare to Cypherpunk Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSTA vs. The Competition

Lisata Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lisata Therapeutics (LSTA) Competitors

LSTA vs. PLYX, AADI, RANI, ENGN, and CYPH

How does Lisata Therapeutics compare to Polaryx Therapeutics?

Which has better valuation and earnings, LSTA or PLYX?

Does the media prefer LSTA or PLYX?

Do analysts rate LSTA or PLYX?

Do insiders & institutionals believe in LSTA or PLYX?

Is LSTA or PLYX more profitable?

Summary

How does Lisata Therapeutics compare to Aadi Bioscience?

Is LSTA or AADI more profitable?

Do analysts recommend LSTA or AADI?

Which has more volatility and risk, LSTA or AADI?

Does the media favor LSTA or AADI?

Do insiders & institutionals have more ownership in LSTA or AADI?

Which has higher valuation and earnings, LSTA or AADI?

Summary

How does Lisata Therapeutics compare to Rani Therapeutics?

Which has more risk & volatility, LSTA or RANI?

Which has stronger earnings & valuation, LSTA or RANI?

Is LSTA or RANI more profitable?

Do analysts recommend LSTA or RANI?

Does the media favor LSTA or RANI?

Do institutionals and insiders have more ownership in LSTA or RANI?

Summary

How does Lisata Therapeutics compare to enGene?

Is ENGN or LSTA more profitable?

Does the media prefer ENGN or LSTA?

Which has more volatility and risk, ENGN or LSTA?

Do analysts rate ENGN or LSTA?

Do institutionals & insiders have more ownership in ENGN or LSTA?

Which has better valuation and earnings, ENGN or LSTA?

Summary

How does Lisata Therapeutics compare to Cypherpunk Technologies?

Which has more risk & volatility, LSTA or CYPH?

Do institutionals & insiders believe in LSTA or CYPH?

Do analysts prefer LSTA or CYPH?

Is LSTA or CYPH more profitable?

Does the media prefer LSTA or CYPH?

Which has better earnings & valuation, LSTA or CYPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSTA vs. The Competition

Lisata Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools